Home › Companies › Gilead Sciences, Inc. › 2025-2026
Download data (CSV): ballot items · votes by manager · column guide.
Compiled from SEC Form N-PX filings and Gilead Sciences, Inc.’s Form 8-K, filed May 4, 2026 (Item 5.07 on EDGAR). Page generated November 20, 2026.
Meeting of April 30, 2026: 15 items on Gilead Sciences, Inc.’s Form 8-K, filed May 4, 2026: 3 approved · 9 passed (calculated) · 3 not approved.
Significant dissent: 1 shareholder proposal (27.1% support).
Dissent tiers, on the company’s own Form 8-K tally (support = FOR ÷ (FOR + AGAINST), or FOR ÷ (FOR + WITHHELD) on a withhold ballot; abstentions and broker non-votes excluded): shareholder proposals with 15% support or more are notable, 25% significant, 40% high; director nominees with 10% or more against or withheld are notable, 20% significant; say-on-pay under 80% support is notable, under 70% significant; equity and compensation plans with 15% or more against are notable, 25% significant; any other item the board put forward with 15% or more against is notable. How this is decided
Explore Gilead Sciences, Inc. in the interactive database Compare manager voting policies
These tallies are Gilead Sciences, Inc.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed May 4, 2026 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.
| Ballot item | For | Against | Abstain | Withheld | Broker non-votes | Support (of votes cast) | Reported outcome | Voting standard |
|---|---|---|---|---|---|---|---|---|
| Elect Director: Jacqueline K. Barton, Ph.D. | 1,013,176,696 | 21,056,724 | 938,657 | -- | 95,008,389 | 98% | Passed (calculated) | — |
| Elect Director: Jeffrey A. Bluestone, Ph.D. | 1,017,337,149 | 16,873,041 | 961,887 | -- | 95,008,389 | 98% | Passed (calculated) | — |
| Elect Director: Sandra J. Horning, M.D. | 1,002,426,858 | 31,078,619 | 1,666,600 | -- | 95,008,389 | 97% | Passed (calculated) | — |
| Elect Director: Kelly A. Kramer | 995,947,854 | 38,240,224 | 983,999 | -- | 95,008,389 | 96% | Passed (calculated) | — |
| Elect Director: Ted W. Love, M.D. | 1,016,607,688 | 17,592,385 | 972,004 | -- | 95,008,389 | 98% | Passed (calculated) | — |
| Elect Director: Harish Manwani | 995,710,468 | 38,469,820 | 991,789 | -- | 95,008,389 | 96% | Passed (calculated) | — |
| Elect Director: Daniel P. O'Day | 980,597,212 | 50,179,985 | 4,394,880 | -- | 95,008,389 | 95% | Passed (calculated) | — |
| Elect Director: Javier J. Rodriguez | 1,019,197,783 | 15,002,200 | 972,094 | -- | 95,008,389 | 99% | Passed (calculated) | — |
| Elect Director: Anthony Welters | 992,619,897 | 40,842,646 | 1,709,534 | -- | 95,008,389 | 96% | Passed (calculated) | — |
| Company's stockholders ratified the selection of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026. The proposal | 1,046,350,569 | 82,831,295 | 998,602 | -- | -- | 93% | Approved | — |
| Company's stockholders approved, on an advisory basis, the compensation of the Company's Named Executive Officers as presented in the Proxy Statement. The proposal | 954,325,805 | 77,503,947 | 3,342,325 | -- | 95,008,389 | 92% | Approved | — |
| Company's stockholders approved the amended and restated Gilead Sciences, Inc. 2022 Equity Incentive Plan. The proposal | 970,290,586 | 62,501,433 | 2,380,058 | -- | 95,008,389 | 94% | Approved | — |
| Company's stockholders did not approve a stockholder proposal requesting an independent Board Chair policy. The proposal | 280,044,780 | 752,716,225 | 2,411,072 | -- | 95,008,389 | 27% | Not approved | — |
| Company's stockholders did not approve a stockholder proposal requesting a report on the impact of extended patent exclusivities on patient access. The proposal | 134,042,210 | 886,986,584 | 14,143,283 | -- | 95,008,389 | 13% | Not approved | — |
| Company's stockholders did not approve a stockholder proposal requesting a report on the risks of ESG and DEI executive compensation metrics. The proposal | 7,262,421 | 1,022,330,186 | 5,579,470 | -- | 95,008,389 | 0.7% | Not approved | — |
Source: Gilead Sciences, Inc., Form 8-K, filed with the SEC on May 4, 2026 — read the filing on EDGAR.
See voting trends for Health Care companies, 2025-2026: shareholder support by sector and by company size.
1,382 asset managers disclosed a vote on at least one Gilead Sciences, Inc. item in their SEC Form N-PX filings. Each item below shows how many of them voted on it, and how. Share totals are the shares those managers' funds voted, summed across every fund they report.
Combines 10 wordings of this item as funds reported it.
98% Majority: yes · of votes cast
Prior year: 98.0% for (May 7, 2025 meeting) ▼ 0.1 pts
Description as filed by funds: To elect the nine director nominees to be named in the Proxy Statement to serve for the next year and until their successors are elected and qualified: Jacqueline K. Barton, Ph.D.
Gilead Sciences, Inc.’s own tally for this item (“Elect Director: Jacqueline K. Barton, Ph.D.”): 1,013,176,696 for, 21,056,724 against, per its Form 8-K filed May 4, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts using a majority of the votes cast, the standard stated in the company’s proxy statement: votes for exceeded votes against.
Support: 98% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 242 asset managers below reported 505,643,431 for, 269 against, 126,542 abstained, 942 not voted, 4,006 unknown.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 114,764,040 | 269 | 11 | 0 | For |
| Fidelity | 78,590,115 | 0 | 0 | 0 | For |
| Capital Group | 67,499,643 | 0 | 0 | 0 | For |
| BlackRock | 49,241,726 | 0 | 0 | 0 | For |
| Invesco | 38,663,991 | 0 | 0 | 0 | For |
| Dodge & Cox | 19,998,392 | 0 | 0 | 0 | For |
| JPMorgan | 15,929,448 | 0 | 0 | 0 | For |
| State Street | 14,747,707 | 0 | 0 | 0 | For |
| T. Rowe Price | 13,108,314 | 0 | 0 | 0 | For |
| Charles Schwab | 7,852,508 | 0 | 0 | 0 | For |
| TIAA | 6,806,803 | 0 | 0 | 0 | For |
| Hartford | 4,760,332 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 4,563,061 | 0 | 0 | 0 | For |
| MFS | 4,442,896 | 0 | 0 | 0 | For |
| American Century | 3,393,694 | 0 | 0 | 0 | For |
| Pacer Funds Trust | 3,288,510 | 0 | 0 | 0 | For |
| First Trust | 3,054,880 | 0 | 0 | 0 | For |
| Jackson National | 2,874,145 | 0 | 0 | 0 | For |
| Dimensional | 2,697,114 | 0 | 0 | 0 | For |
| John Hancock | 2,429,733 | 0 | 0 | 0 | For |
| WisdomTree | 2,216,563 | 0 | 0 | 0 | For |
| INVESTMENT CO OF AMERICA | 1,947,854 | 0 | 0 | 0 | For |
| ProShares | 1,945,965 | 0 | 0 | 0 | For |
| Waddell & Reed | 1,945,339 | 0 | 0 | 0 | For |
| MASTER INVESTMENT PORTFOLIO | 1,914,333 | 0 | 0 | 0 | For |
Showing the 25 largest of 242 asset managers. All 242 are in the interactive database (link above).
Combines 13 wordings of this item as funds reported it.
98% Majority: yes · of votes cast
Prior year: 98.4% for (May 7, 2025 meeting) ▼ 0.1 pts
Description as filed by funds: To elect the nine director nominees to be named in the Proxy Statement to serve for the next year and until their successors are elected and qualified: Jeffrey A. Bluestone, Ph.D.
Gilead Sciences, Inc.’s own tally for this item (“Elect Director: Jeffrey A. Bluestone, Ph.D.”): 1,017,337,149 for, 16,873,041 against, per its Form 8-K filed May 4, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts using a majority of the votes cast, the standard stated in the company’s proxy statement: votes for exceeded votes against.
Support: 98% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 242 asset managers below reported 505,643,486 for, 216 against, 126,542 abstained, 942 not voted, 4,006 unknown.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 114,764,095 | 216 | 11 | 0 | For |
| Fidelity | 78,590,115 | 0 | 0 | 0 | For |
| Capital Group | 67,499,643 | 0 | 0 | 0 | For |
| BlackRock | 49,241,726 | 0 | 0 | 0 | For |
| Invesco | 38,663,991 | 0 | 0 | 0 | For |
| Dodge & Cox | 19,998,392 | 0 | 0 | 0 | For |
| JPMorgan | 15,929,448 | 0 | 0 | 0 | For |
| State Street | 14,747,707 | 0 | 0 | 0 | For |
| T. Rowe Price | 13,108,314 | 0 | 0 | 0 | For |
| Charles Schwab | 7,852,508 | 0 | 0 | 0 | For |
| TIAA | 6,806,803 | 0 | 0 | 0 | For |
| Hartford | 4,760,332 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 4,563,061 | 0 | 0 | 0 | For |
| MFS | 4,442,896 | 0 | 0 | 0 | For |
| American Century | 3,393,694 | 0 | 0 | 0 | For |
| Pacer Funds Trust | 3,288,510 | 0 | 0 | 0 | For |
| First Trust | 3,054,880 | 0 | 0 | 0 | For |
| Jackson National | 2,874,145 | 0 | 0 | 0 | For |
| Dimensional | 2,697,114 | 0 | 0 | 0 | For |
| John Hancock | 2,429,733 | 0 | 0 | 0 | For |
| WisdomTree | 2,216,563 | 0 | 0 | 0 | For |
| INVESTMENT CO OF AMERICA | 1,947,854 | 0 | 0 | 0 | For |
| ProShares | 1,945,965 | 0 | 0 | 0 | For |
| Waddell & Reed | 1,945,339 | 0 | 0 | 0 | For |
| MASTER INVESTMENT PORTFOLIO | 1,914,333 | 0 | 0 | 0 | For |
Showing the 25 largest of 242 asset managers. All 242 are in the interactive database (link above).
Combines 13 wordings of this item as funds reported it.
97% Majority: yes · of votes cast
Prior year: 97.1% for (May 7, 2025 meeting) ▼ 0.1 pts
Description as filed by funds: To elect the nine director nominees to be named in the Proxy Statement to serve for the next year and until their successors are elected and qualified: Sandra J. Horning, M.D.
Gilead Sciences, Inc.’s own tally for this item (“Elect Director: Sandra J. Horning, M.D.”): 1,002,426,858 for, 31,078,619 against, per its Form 8-K filed May 4, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts using a majority of the votes cast, the standard stated in the company’s proxy statement: votes for exceeded votes against.
Support: 97% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 242 asset managers below reported 505,599,363 for, 44,330 against, 126,553 abstained, 942 not voted, 4,006 unknown.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 114,763,923 | 379 | 22 | 0 | For |
| Fidelity | 78,590,115 | 0 | 0 | 0 | For |
| Capital Group | 67,499,643 | 0 | 0 | 0 | For |
| BlackRock | 49,241,726 | 0 | 0 | 0 | For |
| Invesco | 38,663,991 | 0 | 0 | 0 | For |
| Dodge & Cox | 19,998,392 | 0 | 0 | 0 | For |
| JPMorgan | 15,929,448 | 0 | 0 | 0 | For |
| State Street | 14,747,707 | 0 | 0 | 0 | For |
| T. Rowe Price | 13,108,314 | 0 | 0 | 0 | For |
| Charles Schwab | 7,852,508 | 0 | 0 | 0 | For |
| TIAA | 6,806,803 | 0 | 0 | 0 | For |
| Hartford | 4,760,332 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 4,563,061 | 0 | 0 | 0 | For |
| MFS | 4,442,896 | 0 | 0 | 0 | For |
| American Century | 3,393,694 | 0 | 0 | 0 | For |
| Pacer Funds Trust | 3,288,510 | 0 | 0 | 0 | For |
| First Trust | 3,054,880 | 0 | 0 | 0 | For |
| Jackson National | 2,874,145 | 0 | 0 | 0 | For |
| Dimensional | 2,697,114 | 0 | 0 | 0 | For |
| John Hancock | 2,429,733 | 0 | 0 | 0 | For |
| WisdomTree | 2,216,563 | 0 | 0 | 0 | For |
| INVESTMENT CO OF AMERICA | 1,947,854 | 0 | 0 | 0 | For |
| ProShares | 1,945,965 | 0 | 0 | 0 | For |
| Waddell & Reed | 1,945,339 | 0 | 0 | 0 | For |
| MASTER INVESTMENT PORTFOLIO | 1,914,333 | 0 | 0 | 0 | For |
Showing the 25 largest of 242 asset managers. All 242 are in the interactive database (link above).
Combines 10 wordings of this item as funds reported it.
96% Majority: yes · of votes cast
Prior year: 97.1% for (May 7, 2025 meeting) ▼ 0.8 pts
Description as filed by funds: To elect the nine director nominees to be named in the Proxy Statement to serve for the next year and until their successors are elected and qualified: Kelly A. Kramer
Gilead Sciences, Inc.’s own tally for this item (“Elect Director: Kelly A. Kramer”): 995,947,854 for, 38,240,224 against, per its Form 8-K filed May 4, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts using a majority of the votes cast, the standard stated in the company’s proxy statement: votes for exceeded votes against.
Support: 96% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 242 asset managers below reported 505,552,940 for, 90,761 against, 126,543 abstained, 942 not voted, 4,006 unknown.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 114,763,840 | 470 | 12 | 0 | For |
| Fidelity | 78,590,115 | 0 | 0 | 0 | For |
| Capital Group | 67,499,643 | 0 | 0 | 0 | For |
| BlackRock | 49,241,726 | 0 | 0 | 0 | For |
| Invesco | 38,663,991 | 0 | 0 | 0 | For |
| Dodge & Cox | 19,998,392 | 0 | 0 | 0 | For |
| JPMorgan | 15,929,448 | 0 | 0 | 0 | For |
| State Street | 14,747,707 | 0 | 0 | 0 | For |
| T. Rowe Price | 13,108,314 | 0 | 0 | 0 | For |
| Charles Schwab | 7,852,508 | 0 | 0 | 0 | For |
| TIAA | 6,806,803 | 0 | 0 | 0 | For |
| Hartford | 4,760,332 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 4,563,061 | 0 | 0 | 0 | For |
| MFS | 4,442,896 | 0 | 0 | 0 | For |
| American Century | 3,393,694 | 0 | 0 | 0 | For |
| Pacer Funds Trust | 3,288,510 | 0 | 0 | 0 | For |
| First Trust | 3,054,880 | 0 | 0 | 0 | For |
| Jackson National | 2,874,145 | 0 | 0 | 0 | For |
| Dimensional | 2,697,114 | 0 | 0 | 0 | For |
| John Hancock | 2,429,733 | 0 | 0 | 0 | For |
| WisdomTree | 2,216,563 | 0 | 0 | 0 | For |
| INVESTMENT CO OF AMERICA | 1,947,854 | 0 | 0 | 0 | For |
| ProShares | 1,945,965 | 0 | 0 | 0 | For |
| Waddell & Reed | 1,945,339 | 0 | 0 | 0 | For |
| MASTER INVESTMENT PORTFOLIO | 1,914,333 | 0 | 0 | 0 | For |
Showing the 25 largest of 242 asset managers. All 242 are in the interactive database (link above).
Combines 13 wordings of this item as funds reported it.
98% Majority: yes · of votes cast
Prior year: 98.4% for (May 7, 2025 meeting) ▼ 0.1 pts
Description as filed by funds: To elect the nine director nominees to be named in the Proxy Statement to serve for the next year and until their successors are elected and qualified: Ted W. Love, M.D.
Gilead Sciences, Inc.’s own tally for this item (“Elect Director: Ted W. Love, M.D.”): 1,016,607,688 for, 17,592,385 against, per its Form 8-K filed May 4, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts using a majority of the votes cast, the standard stated in the company’s proxy statement: votes for exceeded votes against.
Support: 98% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 242 asset managers below reported 505,643,503 for, 200 against, 126,542 abstained, 942 not voted, 4,006 unknown.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 114,764,112 | 200 | 11 | 0 | For |
| Fidelity | 78,590,115 | 0 | 0 | 0 | For |
| Capital Group | 67,499,643 | 0 | 0 | 0 | For |
| BlackRock | 49,241,726 | 0 | 0 | 0 | For |
| Invesco | 38,663,991 | 0 | 0 | 0 | For |
| Dodge & Cox | 19,998,392 | 0 | 0 | 0 | For |
| JPMorgan | 15,929,448 | 0 | 0 | 0 | For |
| State Street | 14,747,707 | 0 | 0 | 0 | For |
| T. Rowe Price | 13,108,314 | 0 | 0 | 0 | For |
| Charles Schwab | 7,852,508 | 0 | 0 | 0 | For |
| TIAA | 6,806,803 | 0 | 0 | 0 | For |
| Hartford | 4,760,332 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 4,563,061 | 0 | 0 | 0 | For |
| MFS | 4,442,896 | 0 | 0 | 0 | For |
| American Century | 3,393,694 | 0 | 0 | 0 | For |
| Pacer Funds Trust | 3,288,510 | 0 | 0 | 0 | For |
| First Trust | 3,054,880 | 0 | 0 | 0 | For |
| Jackson National | 2,874,145 | 0 | 0 | 0 | For |
| Dimensional | 2,697,114 | 0 | 0 | 0 | For |
| John Hancock | 2,429,733 | 0 | 0 | 0 | For |
| WisdomTree | 2,216,563 | 0 | 0 | 0 | For |
| INVESTMENT CO OF AMERICA | 1,947,854 | 0 | 0 | 0 | For |
| ProShares | 1,945,965 | 0 | 0 | 0 | For |
| Waddell & Reed | 1,945,339 | 0 | 0 | 0 | For |
| MASTER INVESTMENT PORTFOLIO | 1,914,333 | 0 | 0 | 0 | For |
Showing the 25 largest of 242 asset managers. All 242 are in the interactive database (link above).
Combines 10 wordings of this item as funds reported it.
96% Majority: yes · of votes cast
Prior year: 96.2% for (May 7, 2025 meeting) ▲ 0.1 pts
Description as filed by funds: To elect the nine director nominees to be named in the Proxy Statement to serve for the next year and until their successors are elected and qualified: Harish Manwani
Gilead Sciences, Inc.’s own tally for this item (“Elect Director: Harish Manwani”): 995,710,468 for, 38,469,820 against, per its Form 8-K filed May 4, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts using a majority of the votes cast, the standard stated in the company’s proxy statement: votes for exceeded votes against.
Support: 96% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 242 asset managers below reported 505,102,308 for, 541,395 against, 126,543 abstained, 942 not voted, 4,006 unknown.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 114,763,811 | 501 | 12 | 0 | For |
| Fidelity | 78,590,115 | 0 | 0 | 0 | For |
| Capital Group | 67,499,643 | 0 | 0 | 0 | For |
| BlackRock | 49,241,726 | 0 | 0 | 0 | For |
| Invesco | 38,663,991 | 0 | 0 | 0 | For |
| Dodge & Cox | 19,998,392 | 0 | 0 | 0 | For |
| JPMorgan | 15,929,448 | 0 | 0 | 0 | For |
| State Street | 14,747,707 | 0 | 0 | 0 | For |
| T. Rowe Price | 13,108,314 | 0 | 0 | 0 | For |
| Charles Schwab | 7,852,508 | 0 | 0 | 0 | For |
| TIAA | 6,806,803 | 0 | 0 | 0 | For |
| Hartford | 4,760,332 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 4,563,061 | 0 | 0 | 0 | For |
| MFS | 4,442,896 | 0 | 0 | 0 | For |
| American Century | 3,393,694 | 0 | 0 | 0 | For |
| Pacer Funds Trust | 3,288,510 | 0 | 0 | 0 | For |
| First Trust | 3,054,880 | 0 | 0 | 0 | For |
| Jackson National | 2,874,145 | 0 | 0 | 0 | For |
| Dimensional | 2,697,114 | 0 | 0 | 0 | For |
| John Hancock | 2,429,733 | 0 | 0 | 0 | For |
| WisdomTree | 2,216,563 | 0 | 0 | 0 | For |
| INVESTMENT CO OF AMERICA | 1,947,854 | 0 | 0 | 0 | For |
| ProShares | 1,945,965 | 0 | 0 | 0 | For |
| Waddell & Reed | 1,945,339 | 0 | 0 | 0 | For |
| MASTER INVESTMENT PORTFOLIO | 1,914,333 | 0 | 0 | 0 | For |
Showing the 25 largest of 242 asset managers. All 242 are in the interactive database (link above).
Combines 10 wordings of this item as funds reported it.
99% Majority: yes · of votes cast
Prior year: 98.4% for (May 7, 2025 meeting) ▲ 0.1 pts
Description as filed by funds: To elect the nine director nominees to be named in the Proxy Statement to serve for the next year and until their successors are elected and qualified: Javier J. Rodriguez
Gilead Sciences, Inc.’s own tally for this item (“Elect Director: Javier J. Rodriguez”): 1,019,197,783 for, 15,002,200 against, per its Form 8-K filed May 4, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts using a majority of the votes cast, the standard stated in the company’s proxy statement: votes for exceeded votes against.
Support: 99% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 242 asset managers below reported 505,653,512 for, 190 against, 126,542 abstained, 942 not voted, 4,006 unknown.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 114,764,121 | 190 | 11 | 0 | For |
| Fidelity | 78,590,115 | 0 | 0 | 0 | For |
| Capital Group | 67,499,643 | 0 | 0 | 0 | For |
| BlackRock | 49,241,726 | 0 | 0 | 0 | For |
| Invesco | 38,663,991 | 0 | 0 | 0 | For |
| Dodge & Cox | 19,998,392 | 0 | 0 | 0 | For |
| JPMorgan | 15,929,448 | 0 | 0 | 0 | For |
| State Street | 14,747,707 | 0 | 0 | 0 | For |
| T. Rowe Price | 13,108,314 | 0 | 0 | 0 | For |
| Charles Schwab | 7,852,508 | 0 | 0 | 0 | For |
| TIAA | 6,806,803 | 0 | 0 | 0 | For |
| Hartford | 4,760,332 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 4,563,061 | 0 | 0 | 0 | For |
| MFS | 4,442,896 | 0 | 0 | 0 | For |
| American Century | 3,393,694 | 0 | 0 | 0 | For |
| Pacer Funds Trust | 3,288,510 | 0 | 0 | 0 | For |
| First Trust | 3,054,880 | 0 | 0 | 0 | For |
| Jackson National | 2,874,145 | 0 | 0 | 0 | For |
| Dimensional | 2,697,114 | 0 | 0 | 0 | For |
| John Hancock | 2,429,733 | 0 | 0 | 0 | For |
| WisdomTree | 2,216,563 | 0 | 0 | 0 | For |
| INVESTMENT CO OF AMERICA | 1,947,854 | 0 | 0 | 0 | For |
| ProShares | 1,945,965 | 0 | 0 | 0 | For |
| Waddell & Reed | 1,945,339 | 0 | 0 | 0 | For |
| MASTER INVESTMENT PORTFOLIO | 1,914,333 | 0 | 0 | 0 | For |
Showing the 25 largest of 242 asset managers. All 242 are in the interactive database (link above).
Combines 10 wordings of this item as funds reported it.
96% Majority: yes · of votes cast
Prior year: 96.8% for (May 7, 2025 meeting) ▼ 0.7 pts
Description as filed by funds: To elect the nine director nominees to be named in the Proxy Statement to serve for the next year and until their successors are elected and qualified: Anthony Welters
Gilead Sciences, Inc.’s own tally for this item (“Elect Director: Anthony Welters”): 992,619,897 for, 40,842,646 against, per its Form 8-K filed May 4, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts using a majority of the votes cast, the standard stated in the company’s proxy statement: votes for exceeded votes against.
Support: 96% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 242 asset managers below reported 505,578,318 for, 65,873 against, 126,553 abstained, 942 not voted, 4,006 unknown.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 114,763,764 | 536 | 22 | 0 | For |
| Fidelity | 78,590,115 | 0 | 0 | 0 | For |
| Capital Group | 67,499,643 | 0 | 0 | 0 | For |
| BlackRock | 49,241,726 | 0 | 0 | 0 | For |
| Invesco | 38,663,991 | 0 | 0 | 0 | For |
| Dodge & Cox | 19,998,392 | 0 | 0 | 0 | For |
| JPMorgan | 15,929,448 | 0 | 0 | 0 | For |
| State Street | 14,747,707 | 0 | 0 | 0 | For |
| T. Rowe Price | 13,108,314 | 0 | 0 | 0 | For |
| Charles Schwab | 7,852,508 | 0 | 0 | 0 | For |
| TIAA | 6,806,803 | 0 | 0 | 0 | For |
| Hartford | 4,760,332 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 4,563,061 | 0 | 0 | 0 | For |
| MFS | 4,442,896 | 0 | 0 | 0 | For |
| American Century | 3,393,694 | 0 | 0 | 0 | For |
| Pacer Funds Trust | 3,288,510 | 0 | 0 | 0 | For |
| First Trust | 3,054,880 | 0 | 0 | 0 | For |
| Jackson National | 2,874,145 | 0 | 0 | 0 | For |
| Dimensional | 2,697,114 | 0 | 0 | 0 | For |
| John Hancock | 2,429,733 | 0 | 0 | 0 | For |
| WisdomTree | 2,216,563 | 0 | 0 | 0 | For |
| INVESTMENT CO OF AMERICA | 1,947,854 | 0 | 0 | 0 | For |
| ProShares | 1,945,965 | 0 | 0 | 0 | For |
| Waddell & Reed | 1,945,339 | 0 | 0 | 0 | For |
| MASTER INVESTMENT PORTFOLIO | 1,914,333 | 0 | 0 | 0 | For |
Showing the 25 largest of 242 asset managers. All 242 are in the interactive database (link above).
Combines 10 wordings of this item as funds reported it.
95% Majority: yes · of votes cast
Prior year: 93.8% for (May 7, 2025 meeting) ▲ 1.3 pts
Description as filed by funds: To elect the nine director nominees to be named in the Proxy Statement to serve for the next year and until their successors are elected and qualified: Daniel P. O'Day
Gilead Sciences, Inc.’s own tally for this item (“Elect Director: Daniel P. O'Day”): 980,597,212 for, 50,179,985 against, per its Form 8-K filed May 4, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts using a majority of the votes cast, the standard stated in the company’s proxy statement: votes for exceeded votes against.
Support: 95% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 241 asset managers below reported 505,517,311 for, 129,286 against, 126,590 abstained, 942 not voted, 4,006 unknown.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 114,763,633 | 629 | 59 | 0 | For |
| Fidelity | 78,590,115 | 0 | 0 | 0 | For |
| Capital Group | 67,499,643 | 0 | 0 | 0 | For |
| BlackRock | 49,241,726 | 0 | 0 | 0 | For |
| Invesco | 38,663,991 | 0 | 0 | 0 | For |
| Dodge & Cox | 19,998,392 | 0 | 0 | 0 | For |
| JPMorgan | 15,929,448 | 0 | 0 | 0 | For |
| State Street | 14,747,600 | 107 | 0 | 0 | For |
| T. Rowe Price | 13,108,314 | 0 | 0 | 0 | For |
| Charles Schwab | 7,852,508 | 0 | 0 | 0 | For |
| TIAA | 6,806,803 | 0 | 0 | 0 | For |
| Hartford | 4,760,332 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 4,563,061 | 0 | 0 | 0 | For |
| MFS | 4,442,896 | 0 | 0 | 0 | For |
| American Century | 3,393,694 | 0 | 0 | 0 | For |
| Pacer Funds Trust | 3,288,510 | 0 | 0 | 0 | For |
| First Trust | 3,054,880 | 0 | 0 | 0 | For |
| Jackson National | 2,874,145 | 0 | 0 | 0 | For |
| Dimensional | 2,697,114 | 0 | 0 | 0 | For |
| John Hancock | 2,429,733 | 0 | 0 | 0 | For |
| WisdomTree | 2,216,563 | 0 | 0 | 0 | For |
| INVESTMENT CO OF AMERICA | 1,947,854 | 0 | 0 | 0 | For |
| ProShares | 1,945,965 | 0 | 0 | 0 | For |
| Waddell & Reed | 1,945,339 | 0 | 0 | 0 | For |
| MASTER INVESTMENT PORTFOLIO | 1,914,333 | 0 | 0 | 0 | For |
Showing the 25 largest of 241 asset managers. All 241 are in the interactive database (link above).
Combines 8 wordings of this item as funds reported it.
94% Approved · of votes cast
Description as filed by funds: To approve the amended and restated Gilead Sciences, Inc. 2022 Equity Incentive Plan.
Gilead Sciences, Inc.’s own tally for this item (“The Company's stockholders approved the amended and restated Gilead Sciences, Inc. 2022 Equity Incentive Plan. The proposal received the following votes:”): 970,290,586 for, 62,501,433 against — passed, per its Form 8-K filed May 4, 2026 (Item 5.07).
Reported outcome: Approved, in the filing’s own words: “The Company's stockholders approved the amended and restated Gilead Sciences, Inc. 2022 Equity Incentive Plan.”
Support: 94% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
Also reported under other wordings, matched to the same row of Gilead Sciences, Inc.’s official tally and shown with their own fund figures; their managers are not in the figures or the table on this card: “Amend Omnibus Stock Plan” (11 managers, Fund and manager reports combined; may count the same shares twice; no share total shown); “Adopt Incentive Stock Option Plan” (5 managers, Fund and manager reports combined; may count the same shares twice; no share total shown).
The 251 asset managers below reported 501,397,474 for, 4,598,509 against, 126,949 abstained, 942 not voted, 4,006 unknown.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 114,763,639 | 652 | 32 | 0 | For |
| Fidelity | 78,590,115 | 0 | 0 | 0 | For |
| Capital Group | 67,499,643 | 0 | 386 | 0 | For |
| BlackRock | 49,241,726 | 0 | 0 | 0 | For |
| Invesco | 38,663,991 | 0 | 0 | 0 | For |
| Dodge & Cox | 19,998,392 | 0 | 0 | 0 | For |
| JPMorgan | 15,929,448 | 0 | 0 | 0 | For |
| State Street | 14,747,499 | 208 | 0 | 0 | For |
| T. Rowe Price | 13,108,314 | 0 | 0 | 0 | For |
| Charles Schwab | 7,852,508 | 0 | 0 | 0 | For |
| TIAA | 6,806,803 | 0 | 0 | 0 | For |
| Hartford | 4,760,332 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 4,563,061 | 0 | 0 | 0 | For |
| MFS | 4,442,896 | 0 | 0 | 0 | For |
| American Century | 0 | 3,393,694 | 0 | 0 | Against |
| Pacer Funds Trust | 3,288,510 | 0 | 0 | 0 | For |
| First Trust | 3,054,880 | 0 | 0 | 0 | For |
| Jackson National | 2,874,145 | 0 | 0 | 0 | For |
| Dimensional | 2,697,114 | 0 | 0 | 0 | For |
| John Hancock | 2,429,733 | 0 | 0 | 0 | For |
| WisdomTree | 2,216,563 | 0 | 0 | 0 | For |
| INVESTMENT CO OF AMERICA | 1,947,854 | 0 | 0 | 0 | For |
| ProShares | 1,945,965 | 0 | 0 | 0 | For |
| Waddell & Reed | 1,945,339 | 0 | 0 | 0 | For |
| MASTER INVESTMENT PORTFOLIO | 1,914,333 | 0 | 0 | 0 | For |
Showing the 25 largest of 251 asset managers. All 251 are in the interactive database (link above).
Combines 30 wordings of this item as funds reported it.
92% Approved · of votes cast
Prior year: 91.2% for (May 7, 2025 meeting) ▲ 1.3 pts
Description as filed by funds: To approve, on an advisory basis, the compensation of our Named Executive Officers as presented in the Proxy Statement.
Gilead Sciences, Inc.’s own tally for this item (“The Company's stockholders approved, on an advisory basis, the compensation of the Company's Named Executive Officers as presented in the Proxy Statement. The proposal received the following votes:”): 954,325,805 for, 77,503,947 against — passed, per its Form 8-K filed May 4, 2026 (Item 5.07).
Reported outcome: Approved, in the filing’s own words: “The Company's stockholders approved, on an advisory basis, the compensation of the Company's Named Executive Officers as presented in the Proxy Statement.”
Support: 92% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
Also reported under other wordings, matched to the same row of Gilead Sciences, Inc.’s official tally and shown with their own fund figures; their managers are not in the figures or the table on this card: “Say on Pay” (4 managers, 13,649 for, 120,181 against).
Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 114,763,274 | 1,005 | 45 | 0 | For |
| Fidelity | 78,590,115 | 0 | 0 | 0 | For |
| Capital Group | 67,499,643 | 0 | 0 | 0 | For |
| BlackRock | 49,241,726 | 0 | 0 | 0 | For |
| Invesco | 38,663,991 | 0 | 0 | 0 | For |
| Dodge & Cox | 19,998,392 | 0 | 0 | 0 | For |
| JPMorgan | 15,929,448 | 0 | 0 | 0 | For |
| State Street | 14,747,499 | 208 | 0 | 0 | For |
| T. Rowe Price | 13,108,314 | 0 | 0 | 0 | For |
| Charles Schwab | 7,852,508 | 0 | 0 | 0 | For |
| TIAA | 6,806,803 | 0 | 0 | 0 | For |
| Hartford | 4,759,326 | 1,006 | 0 | 0 | For |
| Columbia Threadneedle | 4,563,061 | 0 | 0 | 0 | For |
| MFS | 0 | 4,442,896 | 0 | 0 | Against |
| American Century | 3,393,694 | 0 | 0 | 0 | For |
| Pacer Funds Trust | 3,288,510 | 0 | 0 | 0 | For |
| First Trust | 3,054,880 | 0 | 0 | 0 | For |
| Jackson National | 2,874,145 | 0 | 0 | 0 | For |
| Dimensional | 2,697,114 | 0 | 0 | 0 | For |
| John Hancock | 2,429,733 | 0 | 0 | 0 | For |
| WisdomTree | 2,216,563 | 0 | 0 | 0 | For |
| INVESTMENT CO OF AMERICA | 1,947,854 | 0 | 0 | 0 | For |
| ProShares | 1,945,965 | 0 | 0 | 0 | For |
| Waddell & Reed | 1,945,339 | 0 | 0 | 0 | For |
| MASTER INVESTMENT PORTFOLIO | 1,914,333 | 0 | 0 | 0 | For |
Fund voting reports, all 228 managers: 499,502,891 for, 5,335,772 against, 126,576 abstained, 946 not voted. Showing the 25 largest; every one is in the interactive database (link above).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Fidelity | 64,806,769 | 0 | 0 | 0 | For |
| BlackRock | 58,910,265 | 5,676 | 0 | 0 | For |
| Capital Group | 42,193,272 | 0 | 386 | 0 | For |
| Invesco | 41,411,351 | 40 | 2 | 0 | For |
| State Street | 38,403,415 | 429,258 | 0 | 0 | For |
| GEODE CAPITAL MANAGEMENT, LLC | 29,515,809 | 0 | 0 | 0 | For |
| T. Rowe Price | 28,823,285 | 12,003 | 0 | 0 | For |
| Capital Research Global Investors | 28,581,373 | 0 | 0 | 0 | For |
| Dodge & Cox | 24,231,666 | 0 | 0 | 0 | For |
| Vanguard | 13,028,213 | 0 | 0 | 0 | For |
| Wellington | 12,642,207 | 0 | 0 | 0 | For |
| Northern Trust | 11,478,345 | 100,015 | 0 | 0 | For |
| UBS | 8,446,814 | 0 | 0 | 0 | For |
| Charles Schwab | 8,337,674 | 0 | 0 | 0 | For |
| Nuveen | 7,605,658 | 260 | 0 | 0 | For |
| MELLON INVESTMENTS Corp | 6,831,583 | 0 | 0 | 0 | For |
| Legal & General Investment Management Ltd | 130,711 | 6,140,978 | 0 | 0 | Against |
| Goldman Sachs | 6,218,575 | 0 | 0 | 0 | For |
| Amundi | 0 | 6,203,061 | 0 | 0 | Against |
| MASSACHUSETTS FINANCIAL SERVICES CO /MA/ | 0 | 6,048,355 | 0 | 0 | Against |
| PARAMETRIC PORTFOLIO ASSOCIATES LLC | 5,303,173 | 0 | 0 | 0 | For |
| AllianceBernstein | 5,015,288 | 0 | 0 | 0 | For |
| NORDEA INVESTMENT MANAGEMENT AB | 0 | 4,645,927 | 0 | 0 | Against |
| WELLS FARGO CLEARING SERVICES, LLC | 4,587,651 | 0 | 0 | 0 | For |
| TD ASSET MANAGEMENT INC | 3,940,925 | 0 | 0 | 0 | For |
Institutional-manager reports, all 1,185 managers: 615,044,506 for, 57,872,075 against, 1,194,351 abstained, 344,414 not voted, 4,006 unknown. Showing the 25 largest; every one is in the interactive database (link above).
Combines 5 wordings of this item as funds reported it.
93% Approved · of votes cast
Prior year: 93.0% for (May 7, 2025 meeting) ▼ 0.3 pts
Description as filed by funds: To ratify the selection of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2026.
Gilead Sciences, Inc.’s own tally for this item (“The Company's stockholders ratified the selection of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026. The proposal received the following vote”): 1,046,350,569 for, 82,831,295 against — passed, per its Form 8-K filed May 4, 2026 (Item 5.07).
Reported outcome: Approved, in the filing’s own words: “The Company's stockholders ratified the selection of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026.”
Support: 93% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
Also reported under other wordings, matched to the same row of Gilead Sciences, Inc.’s official tally and shown with their own fund figures; their managers are not in the figures or the table on this card: “Ratify Appointment of Independent Auditors” (7 managers, Fund and manager reports combined; may count the same shares twice; no share total shown).
The 239 asset managers below reported 502,736,904 for, 2,368,674 against, 126,541 abstained, 942 not voted, 4,006 unknown.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 114,652,852 | 111,460 | 10 | 0 | For |
| Fidelity | 78,590,115 | 0 | 0 | 0 | For |
| Capital Group | 67,499,643 | 0 | 0 | 0 | For |
| BlackRock | 49,234,588 | 7,138 | 0 | 0 | For |
| Invesco | 38,663,991 | 0 | 0 | 0 | For |
| Dodge & Cox | 19,998,392 | 0 | 0 | 0 | For |
| JPMorgan | 15,929,448 | 0 | 0 | 0 | For |
| State Street | 14,747,499 | 208 | 0 | 0 | For |
| T. Rowe Price | 13,108,314 | 0 | 0 | 0 | For |
| Charles Schwab | 7,852,508 | 0 | 0 | 0 | For |
| TIAA | 6,806,803 | 0 | 0 | 0 | For |
| Hartford | 4,759,326 | 1,006 | 0 | 0 | For |
| Columbia Threadneedle | 4,563,061 | 0 | 0 | 0 | For |
| MFS | 4,442,896 | 0 | 0 | 0 | For |
| American Century | 3,393,694 | 0 | 0 | 0 | For |
| Pacer Funds Trust | 3,288,510 | 0 | 0 | 0 | For |
| First Trust | 3,054,880 | 0 | 0 | 0 | For |
| Jackson National | 2,598,683 | 275,462 | 0 | 0 | Mixed |
| Dimensional | 2,697,114 | 0 | 0 | 0 | For |
| John Hancock | 2,429,733 | 0 | 0 | 0 | For |
| WisdomTree | 2,216,563 | 0 | 0 | 0 | For |
| INVESTMENT CO OF AMERICA | 1,947,854 | 0 | 0 | 0 | For |
| ProShares | 1,945,965 | 0 | 0 | 0 | For |
| Waddell & Reed | 1,945,339 | 0 | 0 | 0 | For |
| MASTER INVESTMENT PORTFOLIO | 1,914,333 | 0 | 0 | 0 | For |
Showing the 25 largest of 239 asset managers. All 239 are in the interactive database (link above).
Combines 8 wordings of this item as funds reported it.
0.7% Not approved · of votes cast
Description as filed by funds: To vote on a stockholder proposal requesting a report on the risks of ESG and DEI executive compensation metrics, if properly presented at the Annual Meeting.
Gilead Sciences, Inc.’s own tally for this item (“The Company's stockholders did not approve a stockholder proposal requesting a report on the risks of ESG and DEI executive compensation metrics. The proposal received the following votes:”): 7,262,421 for, 1,022,330,186 against — failed, per its Form 8-K filed May 4, 2026 (Item 5.07).
Reported outcome: Not approved, in the filing’s own words: “The Company's stockholders did not approve a stockholder proposal requesting a report on the risks of ESG and DEI executive compensation metrics.”
Support: 0.7% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 255 asset managers below reported 596,912 for, 505,599,598 against, 919,280 abstained, 942 not voted, 4,108 unknown.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 73 | 114,764,176 | 74 | 0 | Against |
| Fidelity | 0 | 78,590,115 | 0 | 0 | Against |
| Capital Group | 0 | 67,499,643 | 0 | 0 | Against |
| BlackRock | 0 | 49,241,726 | 0 | 0 | Against |
| Invesco | 0 | 38,663,991 | 0 | 0 | Against |
| Dodge & Cox | 0 | 19,998,392 | 0 | 0 | Against |
| JPMorgan | 0 | 15,929,448 | 0 | 0 | Against |
| State Street | 0 | 14,747,707 | 0 | 0 | Against |
| T. Rowe Price | 0 | 13,108,314 | 0 | 0 | Against |
| Charles Schwab | 0 | 7,852,508 | 0 | 0 | Against |
| TIAA | 0 | 6,806,803 | 0 | 0 | Against |
| Hartford | 0 | 4,760,332 | 0 | 0 | Against |
| Columbia Threadneedle | 0 | 4,563,061 | 0 | 0 | Against |
| MFS | 0 | 4,442,896 | 0 | 0 | Against |
| American Century | 0 | 3,393,694 | 0 | 0 | Against |
| Pacer Funds Trust | 0 | 3,288,510 | 0 | 0 | Against |
| First Trust | 0 | 3,054,880 | 0 | 0 | Against |
| Jackson National | 0 | 2,874,145 | 0 | 0 | Against |
| Dimensional | 0 | 2,697,114 | 0 | 0 | Against |
| John Hancock | 0 | 2,429,733 | 0 | 0 | Against |
| WisdomTree | 0 | 2,216,563 | 0 | 0 | Against |
| INVESTMENT CO OF AMERICA | 0 | 1,947,854 | 0 | 0 | Against |
| ProShares | 0 | 1,945,965 | 0 | 0 | Against |
| Waddell & Reed | 0 | 1,945,339 | 0 | 0 | Against |
| MASTER INVESTMENT PORTFOLIO | 0 | 1,914,333 | 0 | 0 | Against |
Showing the 25 largest of 255 asset managers. All 255 are in the interactive database (link above).
Combines 5 wordings of this item as funds reported it.
13% Not approved · of votes cast
Description as filed by funds: To vote on a stockholder proposal requesting a report on the impact of extended patent exclusivities on patient access, if properly presented at the Annual Meeting.
Gilead Sciences, Inc.’s own tally for this item (“The Company's stockholders did not approve a stockholder proposal requesting a report on the impact of extended patent exclusivities on patient access. The proposal received the following votes:”): 134,042,210 for, 886,986,584 against — failed, per its Form 8-K filed May 4, 2026 (Item 5.07).
Reported outcome: Not approved, in the filing’s own words: “The Company's stockholders did not approve a stockholder proposal requesting a report on the impact of extended patent exclusivities on patient access.”
Support: 13% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 241 asset managers below reported 4,790,155 for, 499,983,082 against, 981,102 abstained, 942 not voted, 102 unknown.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 111,895 | 114,652,237 | 189 | 0 | Against |
| Fidelity | 0 | 78,590,115 | 0 | 0 | Against |
| Capital Group | 0 | 67,499,643 | 0 | 0 | Against |
| BlackRock | 29,619 | 49,212,107 | 0 | 0 | Against |
| Invesco | 0 | 38,663,991 | 0 | 0 | Against |
| Dodge & Cox | 0 | 19,998,392 | 0 | 0 | Against |
| JPMorgan | 0 | 15,929,448 | 0 | 0 | Against |
| State Street | 4,065 | 14,743,642 | 0 | 0 | Against |
| T. Rowe Price | 0 | 13,108,314 | 0 | 0 | Against |
| Charles Schwab | 0 | 7,852,508 | 0 | 0 | Against |
| TIAA | 0 | 6,806,803 | 0 | 0 | Against |
| Hartford | 1,006 | 4,759,326 | 0 | 0 | Against |
| Columbia Threadneedle | 0 | 4,563,061 | 0 | 0 | Against |
| MFS | 0 | 4,442,896 | 0 | 0 | Against |
| American Century | 0 | 3,393,694 | 0 | 0 | Against |
| Pacer Funds Trust | 0 | 3,288,510 | 0 | 0 | Against |
| First Trust | 0 | 3,054,880 | 0 | 0 | Against |
| Jackson National | 0 | 2,874,145 | 0 | 0 | Against |
| Dimensional | 0 | 2,697,114 | 0 | 0 | Against |
| John Hancock | 0 | 2,429,733 | 0 | 0 | Against |
| WisdomTree | 0 | 2,216,563 | 0 | 0 | Against |
| INVESTMENT CO OF AMERICA | 0 | 1,947,854 | 0 | 0 | Against |
| ProShares | 0 | 1,945,965 | 0 | 0 | Against |
| Waddell & Reed | 0 | 1,945,339 | 0 | 0 | Against |
| MASTER INVESTMENT PORTFOLIO | 0 | 1,914,333 | 0 | 0 | Against |
Showing the 25 largest of 241 asset managers. All 241 are in the interactive database (link above).
Combines 3 wordings of this item as funds reported it.
27% Not approved · of votes cast
Description as filed by funds: To vote on a stockholder proposal requesting an independent Board Chair policy, if properly presented at the Annual Meeting.
Gilead Sciences, Inc.’s own tally for this item (“The Company's stockholders did not approve a stockholder proposal requesting an independent Board Chair policy. The proposal received the following votes:”): 280,044,780 for, 752,716,225 against — failed, per its Form 8-K filed May 4, 2026 (Item 5.07).
Reported outcome: Not approved, in the filing’s own words: “The Company's stockholders did not approve a stockholder proposal requesting an independent Board Chair policy.”
Support: 27% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
Also reported under other wordings, matched to the same row of Gilead Sciences, Inc.’s official tally and shown with their own fund figures; their managers are not in the figures or the table on this card: “Require Independent Board Chair” (11 managers, Fund and manager reports combined; may count the same shares twice; no share total shown).
The 234 asset managers below reported 85,108,391 for, 419,083,408 against, 126,559 abstained, 942 not voted, 102 unknown.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 114,057 | 114,650,238 | 28 | 0 | Against |
| Fidelity | 576,500 | 78,013,615 | 0 | 0 | Against |
| Capital Group | 67,499,643 | 0 | 0 | 0 | For |
| BlackRock | 36,172 | 49,205,554 | 0 | 0 | Against |
| Invesco | 0 | 38,663,991 | 0 | 0 | Against |
| Dodge & Cox | 0 | 19,998,392 | 0 | 0 | Against |
| JPMorgan | 0 | 15,929,448 | 0 | 0 | Against |
| State Street | 4,065 | 14,743,642 | 0 | 0 | Against |
| T. Rowe Price | 0 | 13,108,314 | 0 | 0 | Against |
| Charles Schwab | 2,112 | 7,850,397 | 0 | 0 | Against |
| TIAA | 0 | 6,806,803 | 0 | 0 | Against |
| Hartford | 1,006 | 4,759,326 | 0 | 0 | Against |
| Columbia Threadneedle | 4,563,061 | 0 | 0 | 0 | For |
| MFS | 0 | 4,442,896 | 0 | 0 | Against |
| American Century | 0 | 3,393,694 | 0 | 0 | Against |
| Pacer Funds Trust | 0 | 3,288,510 | 0 | 0 | Against |
| First Trust | 0 | 3,054,880 | 0 | 0 | Against |
| Jackson National | 0 | 2,874,145 | 0 | 0 | Against |
| Dimensional | 0 | 2,697,114 | 0 | 0 | Against |
| John Hancock | 1,843,756 | 585,977 | 0 | 0 | Mixed |
| WisdomTree | 0 | 2,216,563 | 0 | 0 | Against |
| INVESTMENT CO OF AMERICA | 1,947,854 | 0 | 0 | 0 | For |
| ProShares | 0 | 1,945,965 | 0 | 0 | Against |
| Waddell & Reed | 0 | 1,945,339 | 0 | 0 | Against |
| MASTER INVESTMENT PORTFOLIO | 0 | 1,914,333 | 0 | 0 | Against |
Showing the 25 largest of 234 asset managers. All 234 are in the interactive database (link above).
Not shown here: this season’s fund filings also report 2 items from the meeting of May 7, 2025, which belongs to the 2024-2025 season. A meeting outside this season’s July 1 to June 30 window is not counted in this page’s items or in its totals of asset managers and fund votes.
Ranked separately for each type of Form N-PX report. An institutional manager can report shares that a fund it advises also reports, so the two tables can list the same shares and are never added together. Each is ranked by the shares voted on the item that the most managers of that type reported, shown as a share of the 1,242,000,000 shares outstanding at the time of that meeting.
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | Vanguard | 9.24% |
| 2 | Fidelity | 6.33% |
| 3 | Capital Group | 5.43% |
| 4 | BlackRock | 3.96% |
| 5 | Invesco | 3.11% |
| 6 | Dodge & Cox | 1.61% |
| 7 | JPMorgan | 1.28% |
| 8 | State Street | 1.19% |
| 9 | T. Rowe Price | 1.06% |
| 10 | Charles Schwab | 0.63% |
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | Fidelity | 5.22% |
| 2 | BlackRock | 4.74% |
| 3 | Capital Group | 3.40% |
| 4 | Invesco | 3.33% |
| 5 | State Street | 3.13% |
| 6 | GEODE CAPITAL MANAGEMENT, LLC | 2.38% |
| 7 | T. Rowe Price | 2.32% |
| 8 | Capital Research Global Investors | 2.30% |
| 9 | Dodge & Cox | 1.95% |
| 10 | Vanguard | 1.05% |
As disclosed to the SEC in Form 13F (quarter-end holdings of 30 large managers), Schedules 13D and 13G (beneficial ownership above 5%) and the company’s own proxy statement (DEF 14A). Each row gives its source and the date its figure is as of: for Form 13F the quarter end it reports, for Schedules 13D and 13G the filing date, and for the proxy statement the date of its ownership table (or, where that date has not been read, the date the proxy was filed). The rows are therefore not all as of the same day.
| Holder | Shares | % outstanding | Source, as of |
|---|---|---|---|
| The Vanguard Group | 111,820,711 | 9.00% | Proxy statement (DEF 14A), proxy filed March 20, 2026 |
| BlackRock, Inc. | 101,739,273 | 8.19% | Proxy statement (DEF 14A), proxy filed March 20, 2026 |
| FMR LLC | 65,539,477 | 5.28% | Schedule 13G, filed February 5, 2026 |
| State Street | 59,858,585 | 4.82% | Form 13F, quarter ended March 31, 2026 |
| JPMorgan Chase | 33,992,410 | 2.74% | Form 13F, quarter ended March 31, 2026 |
| Gilead Sciences, Inc. | 31,424,760 | 2.53% | Schedule 13D, filed August 7, 2026 |
| Geode Capital | 29,726,052 | 2.39% | Form 13F, quarter ended March 31, 2026 |
| T. Rowe Price | 26,248,108 | 2.11% | Form 13F, quarter ended March 31, 2026 |
| Morgan Stanley | 23,512,734 | 1.89% | Form 13F, quarter ended March 31, 2026 |
| Invesco | 15,526,336 | 1.25% | Form 13F, quarter ended March 31, 2026 |
Percentages above are of 1,242,000,000 shares outstanding, as reported by Gilead Sciences, Inc. on its Form 10-Q dated March 31, 2026 (see the filing on EDGAR). This is the count contemporaneous with the 2025-2026 meeting, not today’s. Each holding is as of its own filing, which may be dated before or after the meeting.
At Gilead Sciences, Inc.'s shareholder meeting held April 30, 2026, in the 2025-2026 proxy season, 1,382 asset managers reported votes on at least one of its 15 ballot items in their SEC Form N-PX filings, covering 23,819 separate fund positions. On the most widely held item on that ballot — To approve, on an advisory basis, the compensation of our Named Executive Officers as presented… — Gilead Sciences, Inc.'s filing reports the proposal as approved, with 92% support of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side). Source: Gilead Sciences, Inc.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on May 4, 2026.
Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered funds disclose how they voted every proxy and institutional managers disclose their votes on executive pay (say-on-pay, say-on-frequency and golden parachutes), and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from Gilead Sciences, Inc.’s 10-Q dated March 31, 2026. This page is a static snapshot rebuilt weekly on November 20, 2026; a live search always shows the current data.
Gilead Sciences, Inc. proxy season coverage: 2023-2024 · 2024-2025 · 2025-2026 (this page).
Proxy Votes Now, “Gilead Sciences (GILD) 2026 Annual Meeting: Shareholder Vote Results”, https://proxyvotesnow.com/company/gilead-sciences-inc/2026 (version of November 20, 2026). Derived from SEC Form N-PX and Form 8-K filings; tables licensed CC BY 4.0. Licence: CC BY 4.0.